Global Hantavirus Market

Hantavirus Comprehensive Study by Type (Sin Nombre, Black Creek Hantavirus, Seoul Virus, New York Hantavirus), Application (Hospitals, Clinics, Intensive Care Unit), Treatment (Mechanical Ventilation, Oxygen Therapy, Supportive Intensive Care), Drugs & Therapeutics (Protocadherin-1 (PCDH1), Methylprednisolone, Prednisolone) Players and Region - Global Market Outlook to 2029

Hantavirus Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Hantavirus Market Scope
Hantavirus is also known as Orthohantavirus, the virus spread mainly by rodents which can lead to hantavirus pulmonary syndrome (HPS) and other respiratory diseases. This causes potentially fatal infections with primary symptoms such as fever, muscle ache, fatigue and later it turns to shortness of breath, cough. The infections occur by breathing air that's contaminated with rodent urine and droppings leading to this infection. There are limited cure and vaccines for the treatment of hantavirus and there has been continuous research regarding the same. Infections with any type of hantavirus can produce severe disease in people, this virus in the Americas is known as "New World" hantaviruses and might cause hantavirus pulmonary syndrome. Other hantaviruses known as "old world" hantavirus are mostly found in Europe and Asia and they might cause hemorrhagic fever with renal syndrome (HFRS).

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledThe Native Antigen Company (United Kingdom), Charles River Laboratories, Inc. (United States), Pfizer Inc. (United States), Thermo Fisher Scientific (United States), Johnson & Johnson (United States) and Sanofi S.A. (France)
CAGR%


Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Hantavirus market throughout the predicted period.

The Native Antigen Company (United Kingdom), Charles River Laboratories, Inc. (United States), Pfizer Inc. (United States), Thermo Fisher Scientific (United States), Johnson & Johnson (United States) and Sanofi S.A. (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are PharmaJet, Inc. (United States) and Cigna (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Hantavirus market by Type , by Application (Hospitals, Clinics and Intensive Care Unit) and Region with country level break-up.

On the basis of geography, the market of Hantavirus has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In March 2023,Pfizer Inc. and Seagen Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines..
In September 2022, Johnson & Johnson (the “Company”) took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company. The new corporate brand comes to life through a compelling purpose, and a timeless visual brand.
According to the CDC, in North America, the incubation period (time from initial exposure to the virus and development of the first symptoms) is between one to five weeks after initial exposure to infected rodent urine, droppings, or saliva. In South American outbreaks, researchers estimate that the incubation period varies from about 12-27 days.

Influencing Trend:
Continuous Research and Development Carrying out in the Laboratories for Effective Treatment and Vaccines

Market Growth Drivers:
Growing Contact of Human with Rodents Infestation, Saliva, Urine, Feces or with Dust and Rural Areas with Large Forests and Fields Increases the Rodents Population

Challenges:
There is Very Limited Treatment, Cure, or Vaccines for the Treatment of Hantavirus Infection

Restraints:
High Risk to People who Are Engaged in the Cleaning Activities Outside with High Exposure to Rodents with Hantavirus Infection

Opportunities:
Awareness About Hantavirus Infection and Increasing Healthcare Funding for Proper Research

Key Target Audience
Hantavirus Treatment Providers, Research and Development Institutes, Potential Investors Treatment, Financial Institution and Venture Capital, Hospitals, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Sin Nombre
  • Black Creek Hantavirus
  • Seoul Virus
  • New York Hantavirus
By Application
  • Hospitals
  • Clinics
  • Intensive Care Unit
By Treatment
  • Mechanical Ventilation
  • Oxygen Therapy
  • Supportive Intensive Care

By Drugs & Therapeutics
  • Protocadherin-1 (PCDH1)
  • Methylprednisolone
  • Prednisolone

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Contact of Human with Rodents Infestation, Saliva, Urine, Feces or with Dust
      • 3.2.2. Rural Areas with Large Forests and Fields Increases the Rodents Population
    • 3.3. Market Challenges
      • 3.3.1. There is Very Limited Treatment, Cure, or Vaccines for the Treatment of Hantavirus Infection
    • 3.4. Market Trends
      • 3.4.1. Continuous Research and Development Carrying out in the Laboratories for Effective Treatment and Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hantavirus, by Type, Application, Treatment, Drugs & Therapeutics and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hantavirus (Value)
      • 5.2.1. Global Hantavirus by: Type (Value)
        • 5.2.1.1. Sin Nombre
        • 5.2.1.2. Black Creek Hantavirus
        • 5.2.1.3. Seoul Virus
        • 5.2.1.4. New York Hantavirus
      • 5.2.2. Global Hantavirus by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Intensive Care Unit
      • 5.2.3. Global Hantavirus by: Treatment (Value)
        • 5.2.3.1. Mechanical Ventilation
        • 5.2.3.2. Oxygen Therapy
        • 5.2.3.3. Supportive Intensive Care
      • 5.2.4. Global Hantavirus by: Drugs & Therapeutics (Value)
        • 5.2.4.1. Protocadherin-1 (PCDH1)
        • 5.2.4.2. Methylprednisolone
        • 5.2.4.3. Prednisolone
      • 5.2.5. Global Hantavirus Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hantavirus: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. The Native Antigen Company (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Charles River Laboratories, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Hantavirus Sale, by Type, Application, Treatment, Drugs & Therapeutics and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Hantavirus (Value)
      • 7.2.1. Global Hantavirus by: Type (Value)
        • 7.2.1.1. Sin Nombre
        • 7.2.1.2. Black Creek Hantavirus
        • 7.2.1.3. Seoul Virus
        • 7.2.1.4. New York Hantavirus
      • 7.2.2. Global Hantavirus by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Intensive Care Unit
      • 7.2.3. Global Hantavirus by: Treatment (Value)
        • 7.2.3.1. Mechanical Ventilation
        • 7.2.3.2. Oxygen Therapy
        • 7.2.3.3. Supportive Intensive Care
      • 7.2.4. Global Hantavirus by: Drugs & Therapeutics (Value)
        • 7.2.4.1. Protocadherin-1 (PCDH1)
        • 7.2.4.2. Methylprednisolone
        • 7.2.4.3. Prednisolone
      • 7.2.5. Global Hantavirus Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hantavirus: by Type(USD Million)
  • Table 2. Hantavirus Sin Nombre , by Region USD Million (2018-2023)
  • Table 3. Hantavirus Black Creek Hantavirus , by Region USD Million (2018-2023)
  • Table 4. Hantavirus Seoul Virus , by Region USD Million (2018-2023)
  • Table 5. Hantavirus New York Hantavirus , by Region USD Million (2018-2023)
  • Table 6. Hantavirus: by Application(USD Million)
  • Table 7. Hantavirus Hospitals , by Region USD Million (2018-2023)
  • Table 8. Hantavirus Clinics , by Region USD Million (2018-2023)
  • Table 9. Hantavirus Intensive Care Unit , by Region USD Million (2018-2023)
  • Table 10. Hantavirus: by Treatment(USD Million)
  • Table 11. Hantavirus Mechanical Ventilation , by Region USD Million (2018-2023)
  • Table 12. Hantavirus Oxygen Therapy , by Region USD Million (2018-2023)
  • Table 13. Hantavirus Supportive Intensive Care , by Region USD Million (2018-2023)
  • Table 14. Hantavirus: by Drugs & Therapeutics(USD Million)
  • Table 15. Hantavirus Protocadherin-1 (PCDH1) , by Region USD Million (2018-2023)
  • Table 16. Hantavirus Methylprednisolone , by Region USD Million (2018-2023)
  • Table 17. Hantavirus Prednisolone , by Region USD Million (2018-2023)
  • Table 18. South America Hantavirus, by Country USD Million (2018-2023)
  • Table 19. South America Hantavirus, by Type USD Million (2018-2023)
  • Table 20. South America Hantavirus, by Application USD Million (2018-2023)
  • Table 21. South America Hantavirus, by Treatment USD Million (2018-2023)
  • Table 22. South America Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 23. Brazil Hantavirus, by Type USD Million (2018-2023)
  • Table 24. Brazil Hantavirus, by Application USD Million (2018-2023)
  • Table 25. Brazil Hantavirus, by Treatment USD Million (2018-2023)
  • Table 26. Brazil Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 27. Argentina Hantavirus, by Type USD Million (2018-2023)
  • Table 28. Argentina Hantavirus, by Application USD Million (2018-2023)
  • Table 29. Argentina Hantavirus, by Treatment USD Million (2018-2023)
  • Table 30. Argentina Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 31. Rest of South America Hantavirus, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Hantavirus, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Hantavirus, by Treatment USD Million (2018-2023)
  • Table 34. Rest of South America Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 35. Asia Pacific Hantavirus, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Hantavirus, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Hantavirus, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Hantavirus, by Treatment USD Million (2018-2023)
  • Table 39. Asia Pacific Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 40. China Hantavirus, by Type USD Million (2018-2023)
  • Table 41. China Hantavirus, by Application USD Million (2018-2023)
  • Table 42. China Hantavirus, by Treatment USD Million (2018-2023)
  • Table 43. China Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 44. Japan Hantavirus, by Type USD Million (2018-2023)
  • Table 45. Japan Hantavirus, by Application USD Million (2018-2023)
  • Table 46. Japan Hantavirus, by Treatment USD Million (2018-2023)
  • Table 47. Japan Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 48. India Hantavirus, by Type USD Million (2018-2023)
  • Table 49. India Hantavirus, by Application USD Million (2018-2023)
  • Table 50. India Hantavirus, by Treatment USD Million (2018-2023)
  • Table 51. India Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 52. South Korea Hantavirus, by Type USD Million (2018-2023)
  • Table 53. South Korea Hantavirus, by Application USD Million (2018-2023)
  • Table 54. South Korea Hantavirus, by Treatment USD Million (2018-2023)
  • Table 55. South Korea Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 56. Taiwan Hantavirus, by Type USD Million (2018-2023)
  • Table 57. Taiwan Hantavirus, by Application USD Million (2018-2023)
  • Table 58. Taiwan Hantavirus, by Treatment USD Million (2018-2023)
  • Table 59. Taiwan Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 60. Australia Hantavirus, by Type USD Million (2018-2023)
  • Table 61. Australia Hantavirus, by Application USD Million (2018-2023)
  • Table 62. Australia Hantavirus, by Treatment USD Million (2018-2023)
  • Table 63. Australia Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Hantavirus, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Hantavirus, by Application USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Hantavirus, by Treatment USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 68. Europe Hantavirus, by Country USD Million (2018-2023)
  • Table 69. Europe Hantavirus, by Type USD Million (2018-2023)
  • Table 70. Europe Hantavirus, by Application USD Million (2018-2023)
  • Table 71. Europe Hantavirus, by Treatment USD Million (2018-2023)
  • Table 72. Europe Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 73. Germany Hantavirus, by Type USD Million (2018-2023)
  • Table 74. Germany Hantavirus, by Application USD Million (2018-2023)
  • Table 75. Germany Hantavirus, by Treatment USD Million (2018-2023)
  • Table 76. Germany Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 77. France Hantavirus, by Type USD Million (2018-2023)
  • Table 78. France Hantavirus, by Application USD Million (2018-2023)
  • Table 79. France Hantavirus, by Treatment USD Million (2018-2023)
  • Table 80. France Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 81. Italy Hantavirus, by Type USD Million (2018-2023)
  • Table 82. Italy Hantavirus, by Application USD Million (2018-2023)
  • Table 83. Italy Hantavirus, by Treatment USD Million (2018-2023)
  • Table 84. Italy Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 85. United Kingdom Hantavirus, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Hantavirus, by Application USD Million (2018-2023)
  • Table 87. United Kingdom Hantavirus, by Treatment USD Million (2018-2023)
  • Table 88. United Kingdom Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 89. Netherlands Hantavirus, by Type USD Million (2018-2023)
  • Table 90. Netherlands Hantavirus, by Application USD Million (2018-2023)
  • Table 91. Netherlands Hantavirus, by Treatment USD Million (2018-2023)
  • Table 92. Netherlands Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 93. Rest of Europe Hantavirus, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Hantavirus, by Application USD Million (2018-2023)
  • Table 95. Rest of Europe Hantavirus, by Treatment USD Million (2018-2023)
  • Table 96. Rest of Europe Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 97. MEA Hantavirus, by Country USD Million (2018-2023)
  • Table 98. MEA Hantavirus, by Type USD Million (2018-2023)
  • Table 99. MEA Hantavirus, by Application USD Million (2018-2023)
  • Table 100. MEA Hantavirus, by Treatment USD Million (2018-2023)
  • Table 101. MEA Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 102. Middle East Hantavirus, by Type USD Million (2018-2023)
  • Table 103. Middle East Hantavirus, by Application USD Million (2018-2023)
  • Table 104. Middle East Hantavirus, by Treatment USD Million (2018-2023)
  • Table 105. Middle East Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 106. Africa Hantavirus, by Type USD Million (2018-2023)
  • Table 107. Africa Hantavirus, by Application USD Million (2018-2023)
  • Table 108. Africa Hantavirus, by Treatment USD Million (2018-2023)
  • Table 109. Africa Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 110. North America Hantavirus, by Country USD Million (2018-2023)
  • Table 111. North America Hantavirus, by Type USD Million (2018-2023)
  • Table 112. North America Hantavirus, by Application USD Million (2018-2023)
  • Table 113. North America Hantavirus, by Treatment USD Million (2018-2023)
  • Table 114. North America Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 115. United States Hantavirus, by Type USD Million (2018-2023)
  • Table 116. United States Hantavirus, by Application USD Million (2018-2023)
  • Table 117. United States Hantavirus, by Treatment USD Million (2018-2023)
  • Table 118. United States Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 119. Canada Hantavirus, by Type USD Million (2018-2023)
  • Table 120. Canada Hantavirus, by Application USD Million (2018-2023)
  • Table 121. Canada Hantavirus, by Treatment USD Million (2018-2023)
  • Table 122. Canada Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 123. Mexico Hantavirus, by Type USD Million (2018-2023)
  • Table 124. Mexico Hantavirus, by Application USD Million (2018-2023)
  • Table 125. Mexico Hantavirus, by Treatment USD Million (2018-2023)
  • Table 126. Mexico Hantavirus, by Drugs & Therapeutics USD Million (2018-2023)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Hantavirus: by Type(USD Million)
  • Table 134. Hantavirus Sin Nombre , by Region USD Million (2024-2029)
  • Table 135. Hantavirus Black Creek Hantavirus , by Region USD Million (2024-2029)
  • Table 136. Hantavirus Seoul Virus , by Region USD Million (2024-2029)
  • Table 137. Hantavirus New York Hantavirus , by Region USD Million (2024-2029)
  • Table 138. Hantavirus: by Application(USD Million)
  • Table 139. Hantavirus Hospitals , by Region USD Million (2024-2029)
  • Table 140. Hantavirus Clinics , by Region USD Million (2024-2029)
  • Table 141. Hantavirus Intensive Care Unit , by Region USD Million (2024-2029)
  • Table 142. Hantavirus: by Treatment(USD Million)
  • Table 143. Hantavirus Mechanical Ventilation , by Region USD Million (2024-2029)
  • Table 144. Hantavirus Oxygen Therapy , by Region USD Million (2024-2029)
  • Table 145. Hantavirus Supportive Intensive Care , by Region USD Million (2024-2029)
  • Table 146. Hantavirus: by Drugs & Therapeutics(USD Million)
  • Table 147. Hantavirus Protocadherin-1 (PCDH1) , by Region USD Million (2024-2029)
  • Table 148. Hantavirus Methylprednisolone , by Region USD Million (2024-2029)
  • Table 149. Hantavirus Prednisolone , by Region USD Million (2024-2029)
  • Table 150. South America Hantavirus, by Country USD Million (2024-2029)
  • Table 151. South America Hantavirus, by Type USD Million (2024-2029)
  • Table 152. South America Hantavirus, by Application USD Million (2024-2029)
  • Table 153. South America Hantavirus, by Treatment USD Million (2024-2029)
  • Table 154. South America Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 155. Brazil Hantavirus, by Type USD Million (2024-2029)
  • Table 156. Brazil Hantavirus, by Application USD Million (2024-2029)
  • Table 157. Brazil Hantavirus, by Treatment USD Million (2024-2029)
  • Table 158. Brazil Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 159. Argentina Hantavirus, by Type USD Million (2024-2029)
  • Table 160. Argentina Hantavirus, by Application USD Million (2024-2029)
  • Table 161. Argentina Hantavirus, by Treatment USD Million (2024-2029)
  • Table 162. Argentina Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 163. Rest of South America Hantavirus, by Type USD Million (2024-2029)
  • Table 164. Rest of South America Hantavirus, by Application USD Million (2024-2029)
  • Table 165. Rest of South America Hantavirus, by Treatment USD Million (2024-2029)
  • Table 166. Rest of South America Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 167. Asia Pacific Hantavirus, by Country USD Million (2024-2029)
  • Table 168. Asia Pacific Hantavirus, by Type USD Million (2024-2029)
  • Table 169. Asia Pacific Hantavirus, by Application USD Million (2024-2029)
  • Table 170. Asia Pacific Hantavirus, by Treatment USD Million (2024-2029)
  • Table 171. Asia Pacific Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 172. China Hantavirus, by Type USD Million (2024-2029)
  • Table 173. China Hantavirus, by Application USD Million (2024-2029)
  • Table 174. China Hantavirus, by Treatment USD Million (2024-2029)
  • Table 175. China Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 176. Japan Hantavirus, by Type USD Million (2024-2029)
  • Table 177. Japan Hantavirus, by Application USD Million (2024-2029)
  • Table 178. Japan Hantavirus, by Treatment USD Million (2024-2029)
  • Table 179. Japan Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 180. India Hantavirus, by Type USD Million (2024-2029)
  • Table 181. India Hantavirus, by Application USD Million (2024-2029)
  • Table 182. India Hantavirus, by Treatment USD Million (2024-2029)
  • Table 183. India Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 184. South Korea Hantavirus, by Type USD Million (2024-2029)
  • Table 185. South Korea Hantavirus, by Application USD Million (2024-2029)
  • Table 186. South Korea Hantavirus, by Treatment USD Million (2024-2029)
  • Table 187. South Korea Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 188. Taiwan Hantavirus, by Type USD Million (2024-2029)
  • Table 189. Taiwan Hantavirus, by Application USD Million (2024-2029)
  • Table 190. Taiwan Hantavirus, by Treatment USD Million (2024-2029)
  • Table 191. Taiwan Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 192. Australia Hantavirus, by Type USD Million (2024-2029)
  • Table 193. Australia Hantavirus, by Application USD Million (2024-2029)
  • Table 194. Australia Hantavirus, by Treatment USD Million (2024-2029)
  • Table 195. Australia Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 196. Rest of Asia-Pacific Hantavirus, by Type USD Million (2024-2029)
  • Table 197. Rest of Asia-Pacific Hantavirus, by Application USD Million (2024-2029)
  • Table 198. Rest of Asia-Pacific Hantavirus, by Treatment USD Million (2024-2029)
  • Table 199. Rest of Asia-Pacific Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 200. Europe Hantavirus, by Country USD Million (2024-2029)
  • Table 201. Europe Hantavirus, by Type USD Million (2024-2029)
  • Table 202. Europe Hantavirus, by Application USD Million (2024-2029)
  • Table 203. Europe Hantavirus, by Treatment USD Million (2024-2029)
  • Table 204. Europe Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 205. Germany Hantavirus, by Type USD Million (2024-2029)
  • Table 206. Germany Hantavirus, by Application USD Million (2024-2029)
  • Table 207. Germany Hantavirus, by Treatment USD Million (2024-2029)
  • Table 208. Germany Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 209. France Hantavirus, by Type USD Million (2024-2029)
  • Table 210. France Hantavirus, by Application USD Million (2024-2029)
  • Table 211. France Hantavirus, by Treatment USD Million (2024-2029)
  • Table 212. France Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 213. Italy Hantavirus, by Type USD Million (2024-2029)
  • Table 214. Italy Hantavirus, by Application USD Million (2024-2029)
  • Table 215. Italy Hantavirus, by Treatment USD Million (2024-2029)
  • Table 216. Italy Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 217. United Kingdom Hantavirus, by Type USD Million (2024-2029)
  • Table 218. United Kingdom Hantavirus, by Application USD Million (2024-2029)
  • Table 219. United Kingdom Hantavirus, by Treatment USD Million (2024-2029)
  • Table 220. United Kingdom Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 221. Netherlands Hantavirus, by Type USD Million (2024-2029)
  • Table 222. Netherlands Hantavirus, by Application USD Million (2024-2029)
  • Table 223. Netherlands Hantavirus, by Treatment USD Million (2024-2029)
  • Table 224. Netherlands Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 225. Rest of Europe Hantavirus, by Type USD Million (2024-2029)
  • Table 226. Rest of Europe Hantavirus, by Application USD Million (2024-2029)
  • Table 227. Rest of Europe Hantavirus, by Treatment USD Million (2024-2029)
  • Table 228. Rest of Europe Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 229. MEA Hantavirus, by Country USD Million (2024-2029)
  • Table 230. MEA Hantavirus, by Type USD Million (2024-2029)
  • Table 231. MEA Hantavirus, by Application USD Million (2024-2029)
  • Table 232. MEA Hantavirus, by Treatment USD Million (2024-2029)
  • Table 233. MEA Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 234. Middle East Hantavirus, by Type USD Million (2024-2029)
  • Table 235. Middle East Hantavirus, by Application USD Million (2024-2029)
  • Table 236. Middle East Hantavirus, by Treatment USD Million (2024-2029)
  • Table 237. Middle East Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 238. Africa Hantavirus, by Type USD Million (2024-2029)
  • Table 239. Africa Hantavirus, by Application USD Million (2024-2029)
  • Table 240. Africa Hantavirus, by Treatment USD Million (2024-2029)
  • Table 241. Africa Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 242. North America Hantavirus, by Country USD Million (2024-2029)
  • Table 243. North America Hantavirus, by Type USD Million (2024-2029)
  • Table 244. North America Hantavirus, by Application USD Million (2024-2029)
  • Table 245. North America Hantavirus, by Treatment USD Million (2024-2029)
  • Table 246. North America Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 247. United States Hantavirus, by Type USD Million (2024-2029)
  • Table 248. United States Hantavirus, by Application USD Million (2024-2029)
  • Table 249. United States Hantavirus, by Treatment USD Million (2024-2029)
  • Table 250. United States Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 251. Canada Hantavirus, by Type USD Million (2024-2029)
  • Table 252. Canada Hantavirus, by Application USD Million (2024-2029)
  • Table 253. Canada Hantavirus, by Treatment USD Million (2024-2029)
  • Table 254. Canada Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 255. Mexico Hantavirus, by Type USD Million (2024-2029)
  • Table 256. Mexico Hantavirus, by Application USD Million (2024-2029)
  • Table 257. Mexico Hantavirus, by Treatment USD Million (2024-2029)
  • Table 258. Mexico Hantavirus, by Drugs & Therapeutics USD Million (2024-2029)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hantavirus: by Type USD Million (2018-2023)
  • Figure 5. Global Hantavirus: by Application USD Million (2018-2023)
  • Figure 6. Global Hantavirus: by Treatment USD Million (2018-2023)
  • Figure 7. Global Hantavirus: by Drugs & Therapeutics USD Million (2018-2023)
  • Figure 8. South America Hantavirus Share (%), by Country
  • Figure 9. Asia Pacific Hantavirus Share (%), by Country
  • Figure 10. Europe Hantavirus Share (%), by Country
  • Figure 11. MEA Hantavirus Share (%), by Country
  • Figure 12. North America Hantavirus Share (%), by Country
  • Figure 13. Global Hantavirus share by Players 2023 (%)
  • Figure 14. Global Hantavirus share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. The Native Antigen Company (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. The Native Antigen Company (United Kingdom) Revenue: by Geography 2023
  • Figure 18. Charles River Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Charles River Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 23. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 24. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 25. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 26. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 28. Global Hantavirus: by Type USD Million (2024-2029)
  • Figure 29. Global Hantavirus: by Application USD Million (2024-2029)
  • Figure 30. Global Hantavirus: by Treatment USD Million (2024-2029)
  • Figure 31. Global Hantavirus: by Drugs & Therapeutics USD Million (2024-2029)
  • Figure 32. South America Hantavirus Share (%), by Country
  • Figure 33. Asia Pacific Hantavirus Share (%), by Country
  • Figure 34. Europe Hantavirus Share (%), by Country
  • Figure 35. MEA Hantavirus Share (%), by Country
  • Figure 36. North America Hantavirus Share (%), by Country
List of companies from research coverage that are profiled in the study
  • The Native Antigen Company (United Kingdom)
  • Charles River Laboratories, Inc. (United States)
  • Pfizer Inc. (United States)
  • Thermo Fisher Scientific (United States)
  • Johnson & Johnson (United States)
  • Sanofi S.A. (France)
Additional players considered in the study are as follows:
PharmaJet, Inc. (United States) , Cigna (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 229 Pages 58 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hantavirus Market Quantitative research analysis
Global Hantavirus Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Hantavirus Market are by type [Sin Nombre, Black Creek Hantavirus, Seoul Virus and New York Hantavirus], by end use application [Hospitals, Clinics and Intensive Care Unit].
The Hantavirus Market is gaining popularity and expected to see strong valuation by 2029.
  • Growing Contact of Human with Rodents Infestation, Saliva, Urine, Feces or with Dust
  • Rural Areas with Large Forests and Fields Increases the Rodents Population

Know More About Global Hantavirus Market Report?

Have a Query? Click Here

Other Related Reports

Edema Clinical Comprehensive Study by Type (Systematic Edema Clinical {Cardiac Disease, Hepatic Disease, Renal Disease, Others}, Local Edema Clinical {Cellulitis, Chronic Venous Insufficiency, Others...
$ 3750
Stereotactic Radiosurgery Comprehensive Study by Application (Brain Tumors, Arteriovenous Malformations (AVMs), Trigeminal Neuralgia, Tremor, Others), End-User (Hospitals, Clinics, Ambulatory Surgery...
$ 3650
Hormone Replacement Therapeutics Comprehensive Study by Type (Estrogen Hormone, Growth Hormone, Thyroid Hormone, Testosterone Hormone), Application (Menopause, Hypothyroidism, Growth Hormone Deficien...
$ 3750
Bone Cancer Treatment Comprehensive Study by Type (Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Dr...
$ 3800
Hemoglobinopathies Comprehensive Study by Type (Thalassemia (Alpha Thalassemia, Beta Thalassemia), Sickle Cell Disease, Other Hb Variants Diseases), Application (Blood Testing, Genetic Testing, Pre-I...
$ 3750
Trigeminal Neuralgia Treatment Comprehensive Study by Type (Medication, Surgery), Application (Hospitals, Clinics, Medical Research Centers), Medicine Type (Anticonvulsant, NSAID's, Opioids, Others),...
$ 3650